$1.06 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 53.7% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
TEVA | TEVA PHARMACEUTICAL INDS LTD | $94,062,000 | +2.5% | 1,750,000 | 0.0% | 8.84% | +47.0% | |
MYL | Buy | MYLAN INC | $63,686,000 | +23.5% | 1,400,000 | +40.0% | 5.98% | +77.2% |
MASI | Buy | MASIMO CORP | $57,456,000 | +33.8% | 2,700,000 | +48.4% | 5.40% | +91.9% |
GHDX | Buy | GENOMIC HEALTH INC | $56,620,000 | +19.8% | 2,000,000 | +15.9% | 5.32% | +71.8% |
GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $55,164,000 | – | 1,200,000 | +100.0% | 5.18% | – |
5100PS | Buy | VOLCANO CORPORATION | $53,732,000 | -3.1% | 5,050,000 | +60.3% | 5.05% | +38.9% |
CNMD | CONMED CORP | $51,023,000 | -16.6% | 1,385,000 | 0.0% | 4.80% | +19.7% | |
ESRX | New | EXPRESS SCRIPTS HLDG CO | $49,441,000 | – | 700,000 | +100.0% | 4.65% | – |
KERX | Buy | KERYX BIOPHARMACEUTICALS INC | $48,125,000 | +4.3% | 3,500,000 | +16.7% | 4.52% | +49.6% |
GSK | New | GLAXOSMITHKLINE PLCcall | $45,970,000 | – | 1,000,000 | +100.0% | 4.32% | – |
VRTX | New | VERTEX PHARMACEUTICALS INC | $44,924,000 | – | 400,000 | +100.0% | 4.22% | – |
OFIX | Buy | ORTHOFIX INTL N V | $37,467,000 | +770.9% | 1,210,164 | +919.7% | 3.52% | +1148.6% |
UAM | UNIVERSAL AMERN CORP NEW | $33,593,000 | -3.5% | 4,178,259 | 0.0% | 3.16% | +38.4% | |
ACHN | Sell | ACHILLION PHARMACEUTICALS IN | $32,435,000 | -26.1% | 3,250,000 | -44.0% | 3.05% | +5.9% |
ARIA | Buy | ARIAD PHARMACEUTICALS INC | $32,400,000 | +1.7% | 6,000,000 | +20.0% | 3.04% | +45.9% |
DGX | Sell | QUEST DIAGNOSTICS INC | $30,340,000 | -53.0% | 500,000 | -54.5% | 2.85% | -32.6% |
WW | Buy | WEIGHT WATCHERS INTL INC NEW | $27,440,000 | +60.1% | 1,000,000 | +17.6% | 2.58% | +129.7% |
TEVA | TEVA PHARMACEUTICAL INDS LTDcall | $26,875,000 | +2.5% | 500,000 | 0.0% | 2.53% | +47.1% | |
AMAG | New | AMAG PHARMACEUTICALS INC | $23,932,000 | – | 750,000 | +100.0% | 2.25% | – |
SQNM | Buy | SEQUENOM INC | $23,760,000 | -2.5% | 8,000,000 | +27.0% | 2.23% | +39.7% |
NVAX | NOVAVAX INC | $19,807,000 | -9.7% | 4,750,000 | 0.0% | 1.86% | +29.4% | |
BRKR | Buy | BRUKER CORP | $18,515,000 | +52.6% | 1,000,000 | +100.0% | 1.74% | +118.9% |
ICUI | ICU MED INC | $17,815,000 | +5.5% | 277,583 | 0.0% | 1.67% | +51.4% | |
BRLI | BIO-REFERENCE LABS INC | $15,257,000 | -7.1% | 543,724 | 0.0% | 1.43% | +33.1% | |
WCG | New | WELLCARE HEALTH PLANS INC | $14,190,000 | – | 235,174 | +100.0% | 1.33% | – |
OTIC | New | OTONOMY INC | $13,752,000 | – | 573,000 | +100.0% | 1.29% | – |
AMRN | Buy | AMARIN CORP PLCspons adr new | $13,080,000 | -32.4% | 12,000,000 | +9.1% | 1.23% | -3.2% |
CCRN | Buy | CROSS CTRY HEALTHCARE INC | $9,290,000 | +78.6% | 1,000,000 | +25.3% | 0.87% | +156.0% |
CRDC | CARDICA INC | $8,961,000 | -6.1% | 8,374,846 | 0.0% | 0.84% | +34.5% | |
GNMK | GENMARK DIAGNOSTICS INC | $8,146,000 | -33.7% | 908,100 | 0.0% | 0.77% | -4.8% | |
PTCT | New | PTC THERAPEUTICS INC | $6,960,000 | – | 158,149 | +100.0% | 0.65% | – |
GERN | Sell | GERON CORP | $6,880,000 | -57.1% | 3,440,045 | -31.2% | 0.65% | -38.5% |
BIOL | BIOLASE INC | $6,761,000 | +13.2% | 2,715,119 | 0.0% | 0.64% | +62.4% | |
ANGO | Sell | ANGIODYNAMICS INC | $5,003,000 | -20.1% | 364,630 | -5.0% | 0.47% | +14.4% |
PLX | PROTALIX BIOTHERAPEUTICS INC | $4,840,000 | -33.7% | 2,000,000 | 0.0% | 0.46% | -4.8% | |
TRGT | TARGACEPT INC | $3,947,000 | -43.9% | 1,560,000 | 0.0% | 0.37% | -19.5% | |
INO | New | INOVIO PHARMACEUTICALS INC | $2,462,000 | – | 250,000 | +100.0% | 0.23% | – |
RPRX | Exit | REPROS THERAPEUTICS INC | $0 | – | -390,370 | -100.0% | -0.44% | – |
TRNX | Exit | TORNIER N V | $0 | – | -573,655 | -100.0% | -0.88% | – |
FURX | Exit | FURIEX PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -1.39% | – |
RVNC | Exit | REVANCE THERAPEUTICS INC | $0 | – | -630,000 | -100.0% | -1.40% | – |
BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -656,900 | -100.0% | -1.66% | – |
HAE | Exit | HAEMONETICS CORP | $0 | – | -1,000,000 | -100.0% | -2.31% | – |
HRC | Exit | HILL ROM HLDGS INC | $0 | – | -893,223 | -100.0% | -2.43% | – |
LH | Exit | LABORATORY CORP AMER HLDGS | $0 | – | -400,000 | -100.0% | -2.68% | – |
THC | Exit | TENET HEALTHCARE CORP | $0 | – | -900,000 | -100.0% | -2.77% | – |
HCA | Exit | HCA HOLDINGS INC | $0 | – | -900,000 | -100.0% | -3.32% | – |
CYH | Exit | COMMUNITY BK SHS IND INC | $0 | – | -1,387,900 | -100.0% | -4.13% | – |
V107SC | Exit | WELLPOINT INC | $0 | – | -700,000 | -100.0% | -4.94% | – |
SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -1,500,000 | -100.0% | -19.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
MYLAN NV | 21 | Q3 2020 | 10.1% |
AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
Solid Biosciences Inc. | December 12, 2022 | ? | ? |
AVROBIO, Inc. | February 14, 2022 | ? | ? |
COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
Change Healthcare Inc. | February 16, 2021 | ? | ? |
GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
SC 13G | 2023-10-30 |
13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.